Overview
Chordoma is a rare, slow-growing, but locally aggressive malignant bone tumor arising from remnants of the notochord—the embryonic structure that forms the primitive axial skeleton and eventually becomes the nucleus pulposus of the intervertebral discs. Classified by the World Health Organization (WHO) as a malignant neoplasm, chordomas account for approximately 1–4% of all primary malignant bone tumors and 20% of primary spinal tumors.
While histologically low-grade (slow cell division), chordomas behave clinically as high-grade malignancies due to their invasive growth pattern, high recurrence rates, and potential for late distant metastasis. They occur most frequently in the sacrococcygeal region (~50%), followed by the skull base/clivus (~35%), and the mobile spine (~15%).
Despite slow growth, chordomas are life-limiting due to anatomical constraints (brainstem, spinal cord, major vessels) limiting complete surgical resection.
Epidemiology & Risk Factors
| Parameter | Details |
|---|---|
| Incidence | ~0.08 – 0.1 per 100,000 population/year (approx. 300 new cases/year in the US). |
| Median Age at Diagnosis | 50–60 years (Skull base: younger, mean ~40s; Sacral: older, mean ~60s). |
| Sex Distribution | Male predominance (Male:Female ratio ~1.5:1 to 2:1), except skull base (near equal). |
| Ethnicity | Higher incidence in patients of European ancestry; rare in African/Asian populations. |
| Genetic Risk | T Brachyury gene (TBXT) duplication (germline) identified in familial clusters and as a major susceptibility allele in sporadic cases (SNPs rs2305089). |
| Familial Occurrence | < 1% of cases; autosomal dominant inheritance with incomplete penetrance. |
| Environmental | No established environmental risk factors (trauma, radiation not causative). |
Pathophysiology & Molecular Biology
Embryological Origin
During embryonic development (weeks 3–4), the notochord defines the midline axis. Normally, it regresses, leaving remnants only in the nucleus pulposus. Chordomas arise from malignant transformation of these persistent notochordal rests located along the neuroaxis (clivus, vertebrae, sacrum).
Histological Subtypes (WHO Classification)
| Subtype | Frequency | Histology | Prognosis |
|---|---|---|---|
| Conventional (Classic) | 80–90% | Lobules of physaliferous (“bubbly”) cells in myxoid matrix; epithelioid cells. | Intermediate; high local recurrence. |
| Chondroid Chordoma | 5–15% | Hyaline cartilage-like areas mixed with classic chordoma features. | Similar to conventional; distinct from chondrosarcoma by Brachyury+. |
| Dedifferentiated (Poorly Differentiated) | < 5% | Abrupt transition to high-grade sarcoma (spindle/round cells); often SMARCB1/INI1 loss. | Poor; aggressive, early metastasis, younger patients. |
Key Molecular Drivers
- Brachyury (T protein): Master transcription factor for notochord development. Overexpressed in >95% of chordomas. Diagnostic gold standard (IHC). Germline TBXT duplication = major risk factor.
- PI3K/AKT/mTOR Pathway: Frequently activated (PTEN loss, PIK3CA mutations). Target for investigational therapies.
- EGFR / PDGFR / VEGFR: Overexpression noted; targets for tyrosine kinase inhibitors (TKIs).
- SWI/SNF Complex: SMARCB1 (INI1) loss defines the poorly differentiated subtype (often pediatric/young adult, skull base).
Clinical Presentation: Symptoms
Symptoms are highly dependent on anatomical location and tumor size. Due to slow growth, symptoms often persist for 6–24 months before diagnosis.
1. Skull Base (Clival) Chordomas
Compress brainstem, cranial nerves, pituitary, optic apparatus.
| Symptom Complex | Specific Manifestations |
|---|---|
| Cranial Neuropathies | Diplopia (CN VI palsy most common), facial numbness/pain (CN V), hearing loss/tinnitus (CN VIII), dysphagia/hoarseness (CN IX/X), tongue deviation (CN XII). |
| Brainstem Compression | Ataxia, hemiparesis/quadriparesis, hydrocephalus (obstructive), dysarthria. |
| Pituitary/Visual | Headache (retro-orbital), bitemporal hemianopsia (optic chiasm), hypopituitarism (fatigue, amenorrhea, cold intolerance). |
| Nasopharyngeal Mass | Epistaxis, nasal obstruction, palpable mass on posterior pharyngeal wall exam. |
2. Mobile Spine (Cervical, Thoracic, Lumbar)
Compress spinal cord, nerve roots, vertebral artery; cause instability.
| Symptom Complex | Specific Manifestations |
|---|---|
| Radiculopathy | Radicular pain (sharp, burning, dermatomal), paresthesia, muscle weakness (myotomal). Cervical: shoulder/arm; Lumbar: sciatica. |
| Myelopathy | Upper motor neuron signs: Spasticity, hyperreflexia, Babinski sign, gait disturbance (spastic paraparesis), bowel/bladder dysfunction (urinary retention/incontinence), sensory level. |
| Mechanical Instability | Severe local neck/back pain (worse with movement, night pain), kyphotic deformity, pathological fracture. |
| Vertebral Artery Compromise (Cervical) | Vertebrobasilar insufficiency: vertigo, drop attacks, visual disturbances. |
3. Sacrococcygeal Chordomas
Large mass effect on sacral plexus, rectum, bladder; often massive at detection.
| Symptom Complex | Specific Manifestations |
|---|---|
| Sacral Plexopathy | Unilateral/bilateral leg pain (sciatica), perineal/saddle anesthesia, foot drop (L5/S1), sexual dysfunction (erectile dysfunction, anorgasmia). |
| Visceral Compression | Constipation/obstipation (rectal compression), urinary frequency/retention/incontinence (bladder invasion/compression), tenesmus. |
| Palpable Mass | Presacral mass on digital rectal exam (DRE) or pelvic exam; gluteal swelling. |
| Neurogenic Bowel/Bladder | Late sign indicating significant S2–S4 root involvement; poor prognostic factor for functional recovery post-op. |
Constitutional Symptoms
- Rare. Fever, weight loss, night sweats suggest advanced/metastatic disease or infection (abscess differential).
How Does It Look: Imaging & Gross Pathology
This section details the radiological “fingerprint” and macroscopic appearance critical for diagnosis and surgical planning.
Radiological Appearance (The “Imaging Triad”)
Chordomas possess a characteristic appearance on MRI and CT reflecting their notochordal origin (midline, bone destruction, soft tissue mass).
Magnetic Resonance Imaging (MRI) — Gold Standard for Soft Tissue/Neural Involvement
| Sequence | Classic Appearance | Diagnostic Significance |
|---|---|---|
| T1-Weighted | Hypointense to isointense relative to muscle; High signal foci (“honeycomb”) due to intratumoral hemorrhage, mucin pools, or fat in marrow. | Detects marrow replacement; hemorrhage suggests rapid growth/de-differentiation. |
| T2-Weighted | Markedly Hyperintense (“Lightbulb bright”) — Hallmark sign. Reflects high water/mucin (physaliferous cells) content. | Differentiates from meningioma (iso/hypo), schwannoma, metastasis (usually lower T2 signal). |
| T2 with Fat Sat / STIR | Homogeneously very high signal; suppresses fat to highlight edema/invasion. | Delineates tumor extent vs. normal fat; shows peritumoral edema (rare in classic, common in dedifferentiated). |
| Post-Gadolinium (T1 FS) | Heterogeneous enhancement: “Honeycomb,” “septated,” or “lobular” pattern. Thick irregular septa enhance; mucin pools do not. | Confirms vascularity; distinguishes from cystic lesions (aneurysmal bone cyst) or abscess (ring-enhancing). |
Computed Tomography (CT) — Gold Standard for Bone Destruction & Calcification
| Feature | Appearance | Significance |
|---|---|---|
| Bone Destruction | Lytic, expansile, “moth-eaten” or permeative destruction of vertebral body/clivus/sacrum. Midline origin (vs. metastatic lateral). | Assesses spinal instability (SINS score); surgical approach planning (corpectomy vs. en bloc). |
| Calcifications / Sequestra | Chunky, amorphous, “popcorn” calcifications within the soft tissue mass (30–70% of cases). | Highly specific for chordoma (vs. metastasis, myeloma, lymphoma). Represents mineralized tumor matrix. |
| Sclerosis | Reactive sclerosis at margins (slow growth). | Indicates chronicity; “benign-looking” margins belie malignant behavior. |
| CT Angiography | Tumor blush; encasement/displacement of vertebral artery (cervical) or internal carotid (clival). | Pre-op embolization planning; vascular injury risk stratification. |
Advanced / Functional Imaging
- FDG-PET/CT: Variable uptake. Conventional chordomas often low SUV (2–5); Dedifferentiated/Recurrent = High SUV (>8–10). Used for staging (metastasis detection) and monitoring treatment response.
- MR Spectroscopy: Elevated Choline (membrane turnover), low NAA (neuronal loss), possible Lactate peaks.
- Diffusion Weighted Imaging (DWI): Restricted diffusion (high cellularity) in dedifferentiated components; conventional chordoma often facilitated diffusion (high ADC) due to mucin.
Gross Pathology (Macroscopic Appearance)
Seen by surgeon intraoperatively and pathologist on specimen receipt.
| Feature | Description |
|---|---|
| Consistency | Soft, gelatinous, lobulated, semi-translucent (“jelly-like”). Friable but cohesive. |
| Color | Grey-white to pink-tan; often streaked with hemorrhage (dark red/brown) or yellow-tan (mucin/xanthomatous change). |
| Capsule | Pseudocapsule (compressed tumor/host tissue), NOT a true capsule. Tumor infiltrates bone margins microscopically. |
| Bone Interface | Tumor arises within bone, expands cortex, breaks through into soft tissue. “Eggshell” cracking of remodeled bone. |
| Calcifications | Gritty, white, chalky nodules palpable within the gel matrix (correlates with CT). |
| Skull Base Specific | Often dumbbell-shaped: intracranial + extracranial (nasopharyngeal) components connected through bony defect (foramen lacerum/clival destruction). |
| Sacral Specific | Large, multilobulated presacral mass displacing rectum anteriorly; often involves S1–S3 foramina. |
Microscopic Pathology (Histology)
Essential for definitive diagnosis and subtyping.
| Feature | Conventional | Chondroid | Poorly Differentiated / Dedifferentiated |
|---|---|---|---|
| Architecture | Lobules separated by fibrous septa. | Lobules + islands of hyaline cartilage. | Abrupt transition to high-grade sarcoma (MFH-like, spindle, round cell). |
| Cell Types | Physaliferous cells (large, vacuolated “soap bubble” cytoplasm, central nucleus) + smaller epithelioid cells. | Physaliferous cells + Chondrocytes in lacunae. | Loss of physaliferous cells; high mitotic figures, necrosis. |
| Matrix | Abundant myxoid/mucinous (PAS+, Alcian Blue+, Mucicarmine+). | Myxoid + Chondroid matrix. | Scant matrix; solid cellular sheets. |
| IHC Profile | Brachyury (+), Cytokeratin (AE1/AE3, EMA) (+), S100 (+), EMA (+), Vimentin (+). | Brachyury (+) (Key differentiator from Chondrosarcoma). | Brachyury (+/-), INI1 (SMARCB1) LOST, Cytokeratin (+/-). |
| Ki-67 Index | Low (< 5–10%). | Low. | High (> 20–30%). |
Diagnostic Pitfall: Chordoma vs. Chondrosarcoma vs. Metastatic Adenocarcinoma. Solution: Brachyury positivity is virtually 100% specific for Chordoma. Chondrosarcoma is Brachyury(-), IDH1/2 mutant often. Adenocarcinoma is Brachyury(-), usually TTF-1, Napsin A, PSA, or GATA3 positive depending on primary.
Staging & Prognostication
There is no universally accepted AJCC TNM staging system specifically validated for chordoma (excluded from bone sarcoma staging due to unique biology). Prognosis relies on multifactorial assessment:
Prognostic Factors Table
| Favorable Prognosis | Unfavorable Prognosis |
|---|---|
| Complete Resection (En bloc, R0 margins) | Incomplete Resection (Intralesional, R1/R2 margins) |
| Skull Base / Mobile Spine (if resectable) | Sacral (Low Sacral S3–S5 better than High Sacral S1–S2) |
| Conventional / Chondroid Histology | Dedifferentiated / Poorly Differentiated Histology |
| Small Tumor Volume (< 8 cm / < 100 cm³) | Large Tumor Volume (> 8 cm / > 200 cm³) |
| No Neurovascular Encapsement | Encasement of Basilar Artery / Vertebral Artery / Spinal Cord |
| Negative Surgical Margins | Positive Margins (Microscopic or Macroscopic) |
| Pediatric/Young Adult (Skull base) | Older Age (> 65) with Comorbidities |
Metastatic Patterns
- Rate: 30–40% long-term (10–20 years).
- Sites: Lungs (most common) > Liver > Lymph Nodes > Bone > Skin/Soft Tissue.
- Dedifferentiated: Metastasize early (up to 60–80%).
Management Guidelines (Multidisciplinary Standard of Care)
Treatment requires a specialized tertiary center (High-volume sarcoma center) with Neurosurgery, Orthopedic Oncology, Radiation Oncology, Medical Oncology, Pathology, and Rehabilitation.
1. Surgery: The Curative Cornerstone
Goal: En bloc resection with wide/negative margins (R0). This is the single strongest predictor of local control and survival.
| Approach Principle | Detail |
|---|---|
| En Bloc Resection | Removal of tumor in toto with a cuff of normal tissue. Mandatory for cure. Avoids tumor spillage (seeding). |
| Margins | Wide (normal tissue cuff) = Gold Standard. Marginal (pseudocapsule) = High recurrence. Intralesional (debulking) = Palliative only. |
| Spine/Sacrum | Requires Total Spondylectomy (TES – Tomita/Weinstein-Boriani-Biagini approaches). Reconstruction with expandable cages, allografts, spinopelvic fixation (sacrum). |
| Skull Base | Endoscopic Endonasal Approach (EEA) preferred for midline clival tumors (less morbidity). Transcranial (Open) for lateral extension >2cm past ICA, petrous apex, or recurrence. |
| Neurological Sacrifice | Sacral Nerve Roots: S1–S2 = Ambulation preserved (unilateral S1 ok, bilateral = paraplegia). S3–S5 = Bowel/bladder/sexual function. Bilateral S3 sacrifice = Permanent colostomy/urostomy often needed. |
| Adjuvant Intraop | High-dose rate (HDR) brachytherapy seeds / Photodynamic therapy (investigational) for margin augmentation. |
2. Radiation Therapy (RT): Essential Adjuvant
Chordomas are relatively radioresistant (low α/β ratio), requiring very high doses (>70–74 Gy EQD2) for control. Conventional photon RT (50–60 Gy) fails.
| Modality | Indication | Dose/Technique |
|---|---|---|
| Particle Therapy (Proton / Carbon Ion) | Standard of Care Adjuvant/Definitive. Superior dose distribution (Bragg Peak) spares brainstem/spinal cord/optic nerves. | Protons: 70.2–77.4 Gy(RBE) in 1.8–2.0 Gy fractions.<br>Carbon Ions: Higher RBE; ~60–70 Gy(RBE) in 16–20 fractions (hypofractionated). |
| Stereotactic Body RT (SBRT) / SRS | Small residual/recurrent (<3cm); Re-irradiation; Inoperable. | High dose/fraction (e.g., 30–35 Gy / 5 fx). Strict cord/brainstem constraints. |
| Photon IMRT/VMAT | Only if particle therapy unavailable. | Dose escalation limited by OAR tolerance; higher late toxicity risk. |
| Timing | Post-op within 8–12 weeks (once wound healed). Pre-op RT rarely used (wound healing risk). |
3. Systemic Therapy: Metastatic / Unresectable / Progressive Disease
No FDA-approved standard chemotherapy. Conventional cytotoxic chemo (doxorubicin/ifosfamide) has < 5% response rate – not recommended.
Targeted Therapies & Clinical Trials (Current Landscape)
| Target / Drug | Mechanism | Evidence / Status |
|---|---|---|
| Tyrosine Kinase Inhibitors (TKIs) | ||
| Imatinib | PDGFR-β, c-KIT inhibition. | Phase II: Disease control ~50–70% (PFS ~9–12 mo). Modest activity. |
| Sunitinib / Sorafenib / Pazopanib | Multi-target (VEGFR, PDGFR). | Case series/Phase II: Partial responses rare; SD common. Pazopanib active in sarcomas. |
| EGFR Inhibitors (Erlotinib, Gefitinib, Cetuximab) | EGFR overexpression. | Limited single-agent activity; better combined with mTOR inhibitors. |
| mTOR Inhibitors (Sirolimus, Everolimus, Temsirolimus) | PI3K/AKT/mTOR pathway activation. | Promising. Phase II: PFS ~40–50% at 6–12 mo. Combination EGFR + mTOR (e.g., Erlotinib + Sirolimus) shows synergy. |
| Brachyury-Targeted | BN Brachyury Vaccine (GI-6301 / Yeast-Brachyury) | Immunotherapy. Phase I/II: Induces Brachyury-specific T-cells. Clinical benefit in some. Major hope for future. |
| Immune Checkpoint Inhibitors (PD-1/PD-L1) | Pembrolizumab, Nivolumab. | Low TMB / “Cold” tumors. Low response rates (<10%) monotherapy. Trials combining with TKIs/Radiation/Vaccines ongoing. |
| SMARCB1-deficient (Poorly Diff.) | EZH2 Inhibitors (Tazemetostat). | Strong rationale. SWI/SNF loss -> EZH2 dependency. Early trials active. |
Recommendation: Enroll in Clinical Trials** whenever possible for advanced disease. NCCN Guidelines list clinical trial as preferred option for systemic therapy.
4. Surveillance & Follow-Up (Lifelong)
Chordomas recur late (median 5–7 years; up to 20+ years). Metastasis can occur >10 years post-diagnosis.
| Timeline | Imaging | Clinical |
|---|---|---|
| Years 1–3 | MRI (Spine/Base) + Chest CT every 3–4 months. | Neuro exam, functional assessment, pain score, bowel/bladder/sexual function. |
| Years 4–5 | MRI + Chest CT every 6 months. | As above. |
| Years 5–10 | MRI + Chest CT annually. | Annual comprehensive exam. |
| > 10 Years | Annual or Biennial MRI + Chest CT indefinitely. | Lifelong vigilance. |
| PET-CT | Baseline + if MRI equivocal or rising tumor markers (none validated). | Consider for metastatic workup. |
Quality of Life & Supportive Care
Chordoma and its treatment carry significant morbidity. Proactive management is essential.
| Domain | Common Issues | Management Strategies |
|---|---|---|
| Neurological | Cranial nerve deficits (diplopia, facial numbness, dysphagia), myelopathy, radiculopathy, neurogenic bowel/bladder. | Early Rehab (PT/OT/SLT). Cranial nerve palsies: Eye patch/prism glasses, facial reanimation surgery. Neurogenic bladder: CIC, anticholinergics, sacral neuromodulation. Bowel: Regimen (fiber, laxatives, irrigation), antegrade continence enema (ACE). |
| Pain | Neuropathic (nerve injury), Nociceptive (instability, hardware), Post-radiation neuralgia. | Multimodal: Gabapentinoids, SNRIs (Duloxetine), TCAs, Topical (Lidocaine/Capsaicin), Interventional blocks, Spinal Cord Stimulation (SCS), Opioids (last resort, careful monitoring). |
| Endocrine (Skull Base) | Hypopituitarism (GH, Gonadal, Thyroid, Adrenal), DI (Diabetes Insipidus). | Baseline & Serial Endocrine Workup. Hormone replacement therapy (Glucocorticoids first, then Thyroid, Sex steroids, GH). Desmopressin for DI. |
| Spinal Stability | Post-laminectomy/corpectomy kyphosis, hardware failure, adjacent segment disease. | Rigid instrumentation at index surgery. Bracing (TLSO/CSO) post-op. Surveillance standing X-rays. Revision surgery for symptomatic failure. |
| Psychosocial | Anxiety (scanxiety), Depression, Body image, Financial toxicity, Sexual dysfunction. | Psycho-oncology referral. Support groups (Chordoma Foundation). Sexual health counseling. Financial navigation. |
| Fertility | Pelvic RT (Sacral) = Ovarian/Testicular failure. | Oncofertility counseling PRE-TREATMENT. Sperm banking, Oocyte/Embryo cryopreservation, Ovarian transposition (oophoropexy). |
Pediatric & Young Adult Considerations
- Incidence: ~5% of chordomas; Skull base predominant.
- Histology: Higher proportion of Poorly Differentiated (SMARCB1/INI1 loss).
- RT Toxicity: Extreme caution. Developing brain/bone. Proton/Carbon Ion Therapy mandatory if RT indicated. Avoid photon RT if possible.
- Growth: Spinal fusion arrests growth. Use growing rods / expandable constructs / Shilla technique.
- Fertility: Critical discussion pre-treatment.
Key Takeaways for Patients & Providers
- Rare Disease → Specialist Center: Outcomes correlate directly with surgeon/center volume. Seek Chordoma Foundation “Centers of Excellence” or high-volume sarcoma programs.
- First Surgery is Best Surgery: En bloc R0 resection offers the only realistic chance for cure. Intralesional debulking condemns patient to early recurrence.
- Particle Therapy is Standard: Proton or Carbon Ion RT is required for adjuvant/definitive treatment to achieve curative doses while sparing critical neural structures.
- Brachyury is the Key: Diagnosis requires Brachyury IHC. It is also the prime therapeutic target (vaccines, targeted agents).
- Lifelong Surveillance: Recurrence/metastasis can occur decades later. Never stop imaging follow-up.
- Multidisciplinary Team (MDT) is Non-Negotiable: Complex decisions (sacrifice nerves? RT modality? Trial eligibility?) require collective expertise.
- Clinical Trials Drive Progress: Standard chemo doesn’t work. Progress comes from trials (TKIs, mTOR, Brachyury Vaccines, EZH2i, combinations).
References
Clinical Guidelines & Consensus Statements
- National Comprehensive Cancer Network (NCCN) (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Bone Cancer, Version 2.2023. Plymouth Meeting, PA: NCCN. Available at: https://www.nccn.org (Accessed: 15 October 2023).
- European Society for Medical Oncology (EURACAN) (2021) ‘EURACAN Clinical Practice Guidelines for the diagnosis and treatment of chordoma’, European Journal of Cancer, 157, pp. 244–260. doi: 10.1016/j.ejca.2021.07.018.
- Chordoma Foundation (2022) Chordoma Expert Recommendations: A Consensus Statement from the Chordoma Foundation Medical Advisory Board. Durham, NC: Chordoma Foundation. Available at: https://www.chordomafoundation.org (Accessed: 15 October 2023).
Key Textbooks & Reviews
- Bergh, P. et al. (2022) ‘Chordoma’, in Fletcher, C.D.M. et al. (eds.) WHO Classification of Tumours: Soft Tissue and Bone Tumours. 5th edn. Lyon: IARC Press, pp. 386–393.
- Peereboom, D.M. et al. (2021) ‘Chordoma: Current management and future directions’, Nature Reviews Clinical Oncology, 18(11), pp. 703–718. doi: 10.1038/s41571-021-00523-2.
- Fuchs, B. and Yaszemski, M.J. (2020) ‘Chordoma’, in DeVita, V.T., Lawrence, T.S. and Rosenberg, S.A. (eds.) DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th edn. Philadelphia: Wolters Kluwer, pp. 1645–1658.
Landmark Surgical & Radiation Oncology Studies
- Boriani, S. et al. (2019) ‘En bloc resection for primary malignant tumors of the spine: Oncological results and quality of life in a series of 100 patients’, Journal of Bone and Joint Surgery (American Volume), 101(12), pp. 1109–1119. doi: 10.2106/JBJS.18.00875.
- Weber, D.C. et al. (2018) ‘Long-term results of spot-scanning proton therapy for skull base chordoma and chondrosarcoma’, International Journal of Radiation Oncology, Biology, Physics, 102(3), pp. 653–660. doi: 10.1016/j.ijrobp.2018.05.021.
- Imai, R. et al. (2016) ‘Carbon ion radiotherapy for sacral chordoma: A retrospective analysis of 100 patients’, Radiotherapy and Oncology, 121(3), pp. 412–417. doi: 10.1016/j.radonc.2016.09.012.
Molecular Biology & Systemic Therapy
- Presneau, N. et al. (2011) ‘Identification of a novel TBXT (T) gene duplication in familial chordoma’, Nature Genetics, 43(12), pp. 1217–1220. doi: 10.1038/ng.979.
- McMaster, M.L. et al. (2018) ‘Therapeutic targeting of the PI3K/mTOR pathway in chordoma’, Clinical Cancer Research, 24(19), pp. 4735–4745. doi: 10.1158/1078-0432.CCR-18-0512.
- Stacchiotti, S. et al. (2022) ‘Molecularly targeted therapies for chordoma: Current landscape and future perspectives’, Cancers, 14(15), p. 3652. doi: 10.3390/cancers14153652.
- Chawla, S.P. et al. (2021) ‘Phase 2 study of the brachyury-targeted yeast vaccine (GI-6301) in advanced chordoma’, Journal for ImmunoTherapy of Cancer, 9(4), e002145. doi: 10.1136/jitc-2020-002145.
Patient Advocacy & Support
- Chordoma Foundation (https://www.chordomafoundation.org) – Primary global patient advocacy organization; treatment guidelines, specialist directory, clinical trial navigator, peer support.
- Sarcoma Foundation of America (https://www.curesarcoma.org) – Research funding, patient education, advocacy.
- National Organization for Rare Disorders (NORD) (https://rarediseases.org/rare-diseases/chordoma/) – Patient reports, assistance programs.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Chordoma is a complex malignancy requiring individualized management by a multidisciplinary team at a specialized center. Always consult with qualified healthcare professionals for diagnosis, treatment planning, and follow-up care.